Mounjaro vs Zepbound

Why Are There Two Brands of Tirzepatide?

Mounjaro and Zepbound are both injectable tirzepatide made by Eli Lilly. They contain the same active molecule -- a dual GIP/GLP-1 receptor agonist that acts on two incretin hormone pathways. Two brand names exist because each FDA-approved indication typically requires its own clinical trial program and labeling.

Eli Lilly first brought tirzepatide to market as Mounjaro for type 2 diabetes, then pursued separate weight-management trials leading to the Zepbound approval. The drug inside the injection pen is the same.

Key Differences at a Glance

Though the molecule is identical, the FDA-approved uses differ:

• Mounjaro received FDA approval in May 2022 to improve glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise.
• Zepbound received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. In December 2024, Zepbound received a supplemental approval for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity -- the first medication approved specifically for this indication.

Unlike the semaglutide brands (Ozempic/Wegovy), which use different dose ranges, Mounjaro and Zepbound share the same doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all once-weekly subcutaneous injections with the same titration schedule.

The Insurance Question

Insurance coverage is where the practical difference becomes most apparent:

• Mounjaro, prescribed for type 2 diabetes, generally has more established coverage under commercial pharmacy benefits. Diabetes medications have well-defined formulary placement, making the coverage pathway more predictable.
• Zepbound, prescribed for weight management or OSA, faces inconsistent coverage. Many plans have historically excluded anti-obesity medications entirely. While this has been changing, coverage remains variable -- some plans cover it with prior authorization, others exclude it, and employer-sponsored plans may differ from marketplace plans.

Because both contain the same drug at the same doses, some patients wonder whether a Mounjaro prescription might be a coverage workaround. A prescription should reflect your actual diagnosis. Prescribing a diabetes medication when the intent is weight management raises ethical and insurance-related concerns, and could complicate your medical record.

Discuss your clinical situation and coverage concerns honestly with your provider.

Lilly Direct Self-Pay Option

To address the coverage gap, Eli Lilly launched a direct-to-patient self-pay option. As of December 2025, Zepbound single-dose vials are available through the Lilly Direct program at $399 per month. Key details:

• The vials require the patient to use a separate syringe, unlike the pre-filled pen format.
• Designed for patients without insurance coverage for Zepbound or who prefer self-pay.
• The $399 price is a significant reduction from the pen's list price.
• Availability and pricing are set by Eli Lilly and may change. Verify current details through the official Lilly Direct website or your provider.

This self-pay option applies only to Zepbound, not Mounjaro.

Can You Switch Between Mounjaro and Zepbound?

Because both contain tirzepatide at the same doses, switching is straightforward pharmacologically. However, practical considerations apply:

• You should not take both Mounjaro and Zepbound at the same time. They are the same drug, and taking both would result in a double dose of tirzepatide, which could be dangerous.
• A switch may be appropriate if your diagnosis or treatment goals change, or if your insurance coverage situation shifts.
• Switching brands will likely require a new prescription and may require new prior authorization from your insurance plan.
• Your healthcare provider should manage any transition between the two brands.

Important Considerations

• Dual mechanism. Tirzepatide is a dual GIP/GLP-1 receptor agonist, distinguishing it from semaglutide (GLP-1 only). This does not necessarily mean one is better -- they have different clinical trial data and limited direct head-to-head comparisons.
• Side effects. Both share the same side effect profile. The most common adverse effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and abdominal pain. Both carry warnings regarding thyroid C-cell tumors based on animal studies and are contraindicated in patients with a history of medullary thyroid carcinoma or MEN type 2.
• Not interchangeable with semaglutide. Tirzepatide and semaglutide are different drugs. Switching between them is not a simple brand swap and requires medical supervision.
• Supply. Tirzepatide products have experienced high demand relative to supply. Availability may vary by dose and location.
• This is not medical advice. Treatment decisions should be made with a qualified healthcare provider.

This page is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the guidance of your physician or other qualified health professional with any questions you may have regarding a medical condition or medication.